CALT 40 (+0%)
US13124Q1067BiotechnologyBiotechnology

Calliditas Therapeutics (CALT) Stock Highlights

40 | +0%
2024-12-21 04:27:43
Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.

Statistics

Range Today
40 40
Volume Today 0
Range 1 Year
15.25 43
Volume 1 Year 2.93M
Range 3 Year
10.82 43
Volume 3 Year 19.03M
Range 10 Year
10.82 43
Volume 10 Year 32.9M

Highlights

Market Capitalization 1.1B (small)
Floating Shares 676.75K
Current Price 40
Price To Earnings -22.73
Price To Revenue 1.48
Price To Book 20.23
Earnings Per Share -1.76
Payout Ratio 0%

Performance

Latest 0%
1 Month -1.09%
3 Months +3.33%
6 Months +83.74%
1 Year +114.13%
3 Years +80.18%
5 Years +101.01%
10 Years +101.01%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.